Downtown New Brunswick is now home to the first tangible piece of what may become one of the most significant life sciences developments anywhere in the state, as the New Jersey Innovation Hub officially opened on July 14, 2026, marking the first phase of a massive 1.5 million square foot development known as HELIX. The acronym stands for the Health and Life Science Exchange, and the broader campus has been designed from the ground up to function as a central meeting point where universities, major corporations, startups, and scientists can collaborate directly on medical research, artificial intelligence, and biotechnology, all within a single, purpose built innovation district.
The Innovation Hub itself occupies 30,000 square feet inside the campus’s first completed tower, known as H-1, and functions as a state of the art life sciences incubator managed by Portal Innovations, a venture capital and development firm that specializes in exactly this kind of shared research infrastructure. Rather than requiring an early stage biotech company to spend millions of dollars building out its own laboratory from scratch, startups can instead rent bench space directly inside the hub, gaining access to more than $2 million worth of advanced lab equipment, private office space, and direct connections to venture capital investors actively looking to fund exactly this kind of early stage research.
The hub launched with a genuinely impressive founding cohort of 16 member companies, each working on distinct, cutting edge projects spanning biotechnology, medical software, environmental technology, and life science advocacy. That opening class represents the complete initial roster for this launch phase, with Portal Innovations confirming that all 16 available slots have now been filled, though several additional companies remain in stealth mode and are expected to publicly reveal their specific medical devices and therapeutic compounds as they scale up their own lab operations inside the hub over the coming months.
The 16 founding member companies are a mix of cutting-edge biotechnology startups, medical software creators, green-tech innovators, and life science advocacy groups.
They make up the very first cohort to move into the brand-new Portal Innovations space at HELIX. The officially revealed members include:
- BioNJ: New Jersey’s massive life sciences trade association, which just signed on as a primary foundational member.
- Scarlet TCR: A biotech firm developing genetically engineered T-cell therapies specifically targeting human papillomavirus (HPV).
- PumpKin Baby: A health-tech startup creating a specialized device that preserves frozen breast milk while actively analyzing its nutritional quality.
- Thrive Genetics: A genomics company utilizing advanced DNA data to improve addiction care through early risk detection and highly personalized treatment plans.
- PFA Solve: An environmental tech company developing new systems to detect, capture, and safely destroy dangerous “forever chemicals” (PFAS contaminants).
- Materium Technologies: A sustainable materials company using machine learning and advanced science to develop high-performance nanocomposite films.
- LeagueMed: A digital marketplace and network that connects healthcare professionals with private, vetted MedTech and Health IT investment opportunities.
- Sampled: A genomics and precision medicine hub focused on helping healthcare organizations unlock the research value of biological samples and data.
- Phase 1 Solutions: A clinical support company that provides hands-on guidance for first-in-human and early-stage drug development trials.
- PharmaMedic: A specialized medical and regulatory consulting firm helping early biotech companies get their products safely through the FDA pipeline.
- Ubuntu Research: A clinical operations company providing trial design and operational strategy support to early-stage pharmaceutical startups.
(Note: Portal Innovations has filled all 16 initial slots for the launch, with the remaining unlisted stealth-mode startups expected to publicly unveil their specific medical devices and therapeutic compounds as they scale up lab operations in the coming months). [1, 2, 3]
Among the officially revealed founding members, BioNJ, the state’s major life sciences trade association, signed on as a primary foundational member, giving the hub immediate institutional credibility within New Jersey’s broader biotech industry. Scarlet TCR is developing genetically engineered T-cell therapies specifically targeting human papillomavirus related cancers, while PumpKin Baby has built a specialized device that preserves frozen breast milk while simultaneously analyzing its nutritional quality, giving new parents a genuinely useful piece of health technology. Thrive Genetics is applying advanced DNA data toward improving addiction care through early risk detection paired with highly personalized treatment plans, and PFA Solve is tackling one of the more pressing environmental health issues of the moment, developing systems specifically designed to detect, capture, and safely destroy dangerous PFAS forever chemicals contaminating drinking water supplies.
Rounding out the founding cohort, Materium Technologies is using machine learning alongside advanced materials science to develop high performance nanocomposite films, while LeagueMed operates as a digital marketplace connecting healthcare professionals directly with vetted MedTech and Health IT investment opportunities. Sampled focuses on genomics and precision medicine, helping healthcare organizations unlock genuine research value from biological samples and associated data, and Phase 1 Solutions provides hands on clinical support specifically for first in human and other early stage drug development trials. PharmaMedic rounds out the regulatory side of the ecosystem, offering specialized medical and regulatory consulting designed to help early biotech companies navigate the FDA approval pipeline safely and efficiently, while Ubuntu Research provides clinical operations support, including trial design and broader operational strategy guidance, for early stage pharmaceutical startups still building out their own internal infrastructure.
The Innovation Hub represents only the very first visible piece of a considerably larger campus vision, one backed by a genuinely substantial public private partnership involving the state of New Jersey, Middlesex County, and several major anchor institutions. Rutgers University is moving its entire Robert Wood Johnson Medical School into this same first tower, bringing advanced Rutgers translational research teams directly into the building alongside the startups housed in the Innovation Hub itself. Perhaps even more significant for the campus’s long term identity, the legendary industrial research company Nokia Bell Labs has broken ground on plans to relocate its entire headquarters, along with a substantial 600,000 square feet of dedicated lab space, into the campus’s planned second phase, known as H-2. Beyond these two anchor tenants, major corporate partners headquartered nearby, including Johnson & Johnson and hospital network RWJBarnabas Health, are deeply embedded throughout the broader HELIX ecosystem, actively mentoring and helping fund the startups working inside the hub.
Given how many of these founding companies operate within biotechnology and medical research, a genuinely important question naturally follows regarding animal testing practices across the cohort. None of the sixteen founding startups engage in any form of testing on wildlife, and the overwhelming majority do not engage in animal testing of any kind whatsoever. Because the Innovation Hub functions primarily as an urban, early stage technology and software incubator, most of its member companies are concentrated heavily around computational data analysis, cell based laboratory research, and environmental engineering, categories of work that simply do not involve living test subjects in the first place.
For a substantial portion of the founding cohort, the absence of animal testing comes down to the basic nature of the technology itself rather than any deliberate ethical policy choice, since the underlying work has nothing to do with injecting or testing on living organisms at all. PFA Solve, for example, works exclusively with chemical systems and advanced filtration technology to safely capture and destroy PFAS contamination in drinking water, an entirely chemistry and engineering based process. Companies like Thrive Genetics and Materium Technologies rely on pure software, artificial intelligence, and existing human genome wide datasets to run virtual machine learning simulations, meaning their core research happens entirely on computers rather than in a traditional wet lab setting. PumpKin Baby similarly focuses on engineering physical hardware designed to safely preserve and analyze human breast milk, a device development process that likewise requires no animal involvement whatsoever.
A smaller subset of the cohort does rely on standard, federally required pre clinical testing methods, a genuinely necessary step for any company developing advanced medicine intended to treat serious human illness. Scarlet TCR’s work modifying human T-cells to aggressively target and destroy cervical cancer tumors represents exactly this kind of case, since verifying that these modified cells actually function correctly and destroy cancer within a complex biological system requires standard pre clinical mouse models during the earliest stages of laboratory research, a requirement the FDA mandates before any such therapy can ever be tested in human patients.
New Jersey’s own state policy reflects a genuine, deliberate priority toward reducing animal testing wherever scientifically possible. Under existing New Jersey law, any form of animal testing specifically for consumer cosmetics products is completely banned outright, one of the clearer statutory signals of the state’s broader position on the issue. Beyond that specific cosmetics ban, the state actively incentivizes startups working within its innovation ecosystem, including those housed at the new Innovation Hub, to adopt advanced non animal testing alternatives whenever federally permitted, including high tech engineered human tissue models, synthetic organoids, and increasingly sophisticated computer based modeling techniques, positioning New Jersey’s newest life sciences hub at the intersection of cutting edge medical research and a genuinely forward looking approach to research ethics.
With Rutgers relocating its medical school into the same building, Nokia Bell Labs preparing its own major campus expansion nearby, and sixteen genuinely diverse startups already at work inside the Innovation Hub itself, HELIX’s opening phase signals considerably more than a single building coming online in downtown New Brunswick. It represents the first visible step in what state and county officials clearly intend to become one of the most significant life sciences and technology hubs anywhere on the East Coast, built on a foundation that pairs genuine scientific ambition with a deliberate commitment to responsible, forward thinking research practices.
